Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment

Mayo Clinic Proceedings

Volumn 91, Issue 3, 2016, Pages 386-396

  Marur, Shanthi ^a   Forastiere, Arlene A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PANITUMUMAB; PLATINUM COMPLEX; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG MEGADOSE; DYSPHAGIA; GENOME ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; META ANALYSIS (TOPIC); MINIMALLY INVASIVE SURGERY; MULTIMODALITY CANCER THERAPY; OROPHARYNX CANCER; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; RECURRENT ASPIRATION; REVIEW; RISK ASSESSMENT; TRANSORAL ROBOTIC SURGERY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS CARCINOGENESIS; XEROSTOMIA; ADJUVANT RADIOTHERAPY; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; PATHOLOGY; UNITED STATES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 84959349850     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.12.017     Document Type: Review

References (57)

1. L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal Global cancer statistics, 2012 CA Cancer J Clin 65 2 2015 87 108
2. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 1 2015 5 29
3. S. Marur, and A.A. Forastiere Head and neck cancer: changing epidemiology, diagnosis, and treatment [published correction appears in Mayo Clin Proc. 2008;83(5):604] Mayo Clin Proc 83 4 2008 489 501
4. E.M. Sturgis, and P.M. Cinciripini Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 110 7 2007 1429 1435
5. M.L. Gillison, T. Broutian, R.K. Pickard, and et al. Prevalence of oral HPV infection in the United States, 2009-2010 JAMA 307 7 2012 693 703
6. A.K. Chaturvedi, E.A. Engels, R.M. Pfeiffer, and et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 29 32 2011 4294 4301
7. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER 9 registries, Cancer Statistics Animator. National Cancer Institute website. http://seer.cancer.gov/canstat. Updated August 2014. Accessed March 3, 2015.
8. M.L. Gillison, X. Castellsagué, A. Chaturvedi, and et al. EUROGIN roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix Int J Cancer 134 3 2014 497 507
9. A.K. Chaturvedi, W.F. Anderson, J. Lortet-Tieulent, and et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers J Clin Oncol 31 36 2013 4550 4559
10. G. D'Souza, A.R. Kreimer, R. Viscidi, and et al. Case-control study of human papillomavirus and oropharyngeal cancer N Engl J Med 356 19 2007 1944 1956
11. C. Fakhry, W.H. Westra, S. Li, and et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial J Natl Cancer Inst 100 4 2008 261 269
12. S. Marur, G. D'Souza, W.H. Westra, and A.A. Forastiere HPV-associated head and neck cancer: a virus-related cancer epidemic Lancet Oncol 11 8 2010 781 789
13. C.R. Leemans, B.J. Braakhuis, and R.H. Brakenhoff The molecular biology of head and neck cancer Nat Rev Cancer 11 1 2011 9 22
14. L. Vidal, and M.L. Gillison Human papillomavirus in HNSCC: recognition of a distinct disease type Hematol Oncol Clin North Am 22 6 2008 1125 1142 vii
15. H.S. Zhang, A.A. Postigo, and D.C. Dean Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition Cell 97 1 1999 53 61
16. A. Venuti, and F. Paolini HPV detection methods in head and neck cancer Head Neck Pathol 6 suppl 1 2012 S63 S74
17. S.J. Smeets, A.T. Hesselink, E.J. Speel, and et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen Int J Cancer 121 11 2007 2465 2472
18. M. Lechner, T. Fenton, J. West, and et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma Genome Med 5 2 2013 15
19. N. Agrawal, M.J. Frederick, C.R. Pickering, and et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 333 6046 2011 1154 1157
20. M. Lechner, G.M. Frampton, T. Fenton, and et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors Genome Med 5 5 2013 49
21. Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas Nature 517 7536 2015 576 582
22. C. Laubenbacher, D. Saumweber, C. Wagner-Manslau, and et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas J Nucl Med 36 10 1995 1747 1757
23. S. Sheikhbahaei, M. Taghipour, R. Ahmad, and et al. Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and meta-analysis AJR Am J Roentgenol 205 3 2015 629 639
24. M. Yao, R.B. Smith, H.T. Hoffman, and et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer - a long-term outcome report Int J Radiat Oncol Biol Phys 74 1 2009 9 14
25. S.V. Porceddu, E. Jarmolowski, R.J. Hicks, and et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer Head Neck 27 3 2005 175 181
26. D.G. Pfister, K.K. Ang, D.M. Brizel, et al. National Comprehensive Cancer Network Head and neck cancers, version 2.2013: featured updates to the NCCN guidelines [published correction appears in J Natl Compr Canc Netw. 2013;11(12):1458] J Natl Compr Canc Netw 11 8 2013 917 923
27. B. Kofler, S. Laban, C.J. Busch, B. Lörincz, and R. Knecht New treatment strategies for HPV-positive head and neck cancer Eur Arch Otorhinolaryngol 271 7 2014 1861 1867
28. M.A. Cohen, G.S. Weinstein, B.W. O'Malley Jr., M. Feldman, and H. Quon Transoral robotic surgery and human papillomavirus status: oncologic results Head Neck 33 4 2011 573 580
29. P.F. Nguyen-Tan, Q. Zhang, K.K. Ang, and et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity J Clin Oncol 32 34 2014 3858 3866
30. J.A. Langendijk, P. Doornaert, I.M. Verdonck-de Leeuw, C.R. Leemans, N.K. Aaronson, and B.J. Slotman Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy J Clin Oncol 26 22 2008 3770 3776
31. G. Vlacich, D.E. Spratt, R. Diaz, and et al. Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer Radiother Oncol 110 3 2014 435 440
32. J.P. Pignon, J. Bourhis, C. Domenge, L. Designé MACH-NC Collaborative Group Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data Lancet 355 9208 2000 949 955
33. P. Blanchard, B. Baujat, V. Holostenco, et al. MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site Radiother Oncol 100 1 2011 33 40
34. J.A. Bonner, P.M. Harari, J. Giralt, and et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578
35. J.A. Bonner, P.M. Harari, J. Giralt, and et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [published correction appears in Lancet Oncol. 2010;11(1):14] Lancet Oncol 11 1 2010 21 28
36. K.K. Ang, Q. Zhang, D.I. Rosenthal, and et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 J Clin Oncol 32 27 2014 2940 2950
37. J. Giralt, J. Trigo, S. Nuyts, and et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial Lancet Oncol 16 2 2015 221 232
38. A.A. Forastiere, H. Goepfert, M. Maor, and et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 22 2003 2091 2098
39. A.A. Forastiere, Q. Zhang, R.S. Weber, and et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer J Clin Oncol 31 7 2013 845 852
40. A.A. Forastiere, R.S. Weber, and A. Trotti Organ preservation for advanced larynx cancer: issues and outcomes J Clin Oncol 33 29 2015 3262 3268
41. G. Calais, E. Bardet, C. Sire, and et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma: results of the 98-02 GORTEC Phase II trial Int J Radiat Oncol Biol Phys 58 1 2004 161 166
42. F. Denis, P. Garaud, E. Bardet, and et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma J Clin Oncol 22 1 2004 69 76
43. K.K. Ang, J. Harris, R. Wheeler, and et al. Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 1 2010 24 35
44. B. O'Sullivan, S.H. Huang, L.L. Siu, and et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis J Clin Oncol 31 5 2013 543 550
45. A. Cmelak, S. Li, S. Marur, and et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC) J Clin Oncol 32 suppl 2014 5s Abstract LBA6006
46. S.H. Huang, W. Xu, J. Waldron, and et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas J Clin Oncol 33 8 2015 836 845
47. M.R. Posner, D.M. Hershock, C.R. Blajman, et al. TAX 324 Study Group Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 17 2007 1705 1715
48. J.B. Vermorken, E. Remenar, C. van Herpen, et al. EORTC 24971/TAX 323 Study Group Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 17 2007 1695 1704
49. P. Blanchard, J. Bourhis, B. Lacas, et al. Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group J Clin Oncol 31 23 2013 2854 2860
50. J.L. Lefebvre, Y. Pointreau, F. Rolland, and et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study [published correction appears in J Clin Oncol. 2013;31(13):1702] J Clin Oncol 31 7 2013 853 859
51. R. Haddad, A. O'Neill, G. Rabinowits, and et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial Lancet Oncol 14 3 2013 257 264
52. E.E. Cohen, T.G. Karrison, M. Kocherginsky, and et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer J Clin Oncol 32 25 2014 2735 2743
53. B. Burtness, J.E. Bauman, and T. Galloway Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition Lancet Oncol 14 8 2013 e302 e309
54. T.J. Galloway, L.J. Wirth, A.D. Colevas, and et al. A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma Clin Cancer Res 21 7 2015 1566 1573
55. J.B. Vermorken, J. Trigo, R. Hitt, and et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 16 2007 2171 2177
56. E.E. Cohen, M.A. Kane, M.A. List, and et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Clin Cancer Res 11 23 2005 8418 8424
57. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 1 2004 77 85